Compare STEP & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEP | LQDA |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.4B |
| IPO Year | 2020 | 2020 |
| Metric | STEP | LQDA |
|---|---|---|
| Price | $52.95 | $61.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 11 |
| Target Price | ★ $71.00 | $41.00 |
| AVG Volume (30 Days) | 748.2K | ★ 1.5M |
| Earning Date | 05-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | N/A | ★ 0.52 |
| Revenue | ★ $1,174,830,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $26.41 | $57.13 |
| P/E Ratio | ★ N/A | $119.19 |
| Revenue Growth | 65.09 | ★ 1031.18 |
| 52 Week Low | $40.58 | $11.85 |
| 52 Week High | $77.80 | $62.30 |
| Indicator | STEP | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.44 | 80.46 |
| Support Level | $49.48 | $31.23 |
| Resistance Level | $57.40 | N/A |
| Average True Range (ATR) | 2.10 | 3.75 |
| MACD | -0.32 | 1.28 |
| Stochastic Oscillator | 23.48 | 96.68 |
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.